mouse pf4 elisa kit (Elabscience Biotechnology)
Structured Review

Mouse Pf4 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/platelet+factor+4/Mouse+PF4+(Platelet+Factor+4)+ELISA+Kit/pmc12901762-237-8-12
Average 94 stars, based on 6 article reviews
Images
1) Product Images from "TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms"
Article Title: TLR8 agonists remodel the tumor immune microenvironment through PF4-dependent T cell recruitment and ancillary mechanisms
Journal: Cancer Immunology, Immunotherapy : CII
doi: 10.1007/s00262-026-04329-8
Figure Legend Snippet: TLR8 agonist activates PF4-CXCR3 pathway to shape the TIME. A t-SNE plot showing the distribution of all cells from the control and agonist-treated groups combined ( n = 15,745 cells). B t-SNE plot depicting the distribution of distinct immune cell types. C Dot plot displaying the marker genes used to define each immune cell population. D Density plot showing the distribution of Tlr8-expressing cells across the t-SNE map. E Violin plot illustrating Tlr8 expression levels across different immune cell types. F Circle plot depicting the strength of Pf4–Cxcr3 receptor–ligand interactions between distinct cell types in the control and motolimod-treated groups. G Differential gene expression profiles of neutrophils, macrophages, cDC2, and CD8 + T cells. H Bubble plot comparing changes in specific receptor–ligand interactions between the control and motolimod-treated groups, focusing on macrophage-to-cCD4 + T signaling, cDC2-to-cCD4 + T signaling, and CD8 + T-to-cCD4 + T signaling. I Violin plot showing differential expression of Cxcr3 in cCD4 + T and Tregs, analyzed using the Wilcoxon rank-sum test. ns, not significant; ** P < 0.01
Techniques Used: Control, Marker, Expressing, Gene Expression, Quantitative Proteomics
Figure Legend Snippet: TLR8 agonist induces PF4 expression through NF-κB signaling pathway. A , B qRT-PCR analysis of Pf4 expression in mouse and human macrophages in the motolimod-treated and control groups ( n = 3). C , D Luminescence assay showing NF-κB pathway activation in mouse and human macrophages following motolimod stimulation ( n = 3). E , F qRT-PCR analysis of Rela expression in Rela -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). G , H Western blotting showing p65 protein levels in RELA -knockdown and control mouse and human macrophages with or without motolimod treatment. I , J qRT-PCR analysis of Pf4 / PF4 expression in Rela / RELA -knockdown and control mouse and human macrophages with or without motolimod treatment ( n = 3). K ELISA quantification of Pf4 levels in the culture supernatant from Rela -knockdown and control mouse macrophages with or without motolimod treatment ( n = 3). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
Techniques Used: Expressing, Quantitative RT-PCR, Control, Luminescence Assay, Activation Assay, Knockdown, Western Blot, Enzyme-linked Immunosorbent Assay
Figure Legend Snippet: PF4 remodels the TIME and suppresses tumor growth. A , B Tumor growth curves and terminal tumor weights in C57BL/6 mice bearing AKR or MC38 tumors with or without Pf4 overexpression, treated with or without motolimod administered every three days ( n = 6). C Percentage of CD45 + cells among live cells in AKR and MC38 tumor models ( n = 6). D Percentage of cCD4 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). E Percentage of CD8 + T cells within the CD45 + population in AKR and MC38 tumor models ( n = 6). F Percentage of Tregs within the CD45 + population in AKR and MC38 tumor models ( n = 6). G Ratios of cCD4 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). H Ratios of CD8 + T cells to Tregs in AKR and MC38 tumor models ( n = 6). I Representative immunofluorescence staining of CD8α (red) and DAPI (blue) in MC38-Vector or MC38-Pf4-OE tumor sections with or without motolimod treatment. Scale bar: 50 μm. J Quantification of CD8α + positive cell ratio (%) relative to total DAPI + nucleated cells per section ( n = 6). Data represent the mean ± SEM. Statistical comparisons were performed using Student’s t-tests. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001
Techniques Used: Over Expression, Immunofluorescence, Staining, Plasmid Preparation
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Mediterranean Diet and Atherothrombosis Biomarkers: A Randomized Controlled Trial. Article Snippet: .. [1,27] Atherothrombosis Biomarkers: ELISA kits were used to quantify the levels of: fibrinogen (Human Fibrinogen SimpleStep ELISA kit, ref. ab208036, abcam, UK), PAI-1 (Human PAI1 SimpleStep ELISA kit (SERPINE1), ref. ab184863, abcam, UK), platelet factor-4 (PF4 (CXCL4) Human SimpleStep ELISA kit, ref. ab189573, abcam, UK), and prothrombin fragment 1+2 (Human F1+2 (prothrombin fragment 1+2) ELISA kit, ref. |
![(a) Effects of complement inhibitors on complement activation by KKO ICs. Healthy donor plasma was pre-incubated with complement inhibitors (BBK32, a small molecule C1 inhibitor, 25 μg/ml), C1-esterase inhibitor (C1-INH, 100 μg/ml), Cp40 (a C3 inhibitor, 20 μM), anti-C1q blocking antibody (300 μg/ml), IV.3 (10 μg/ml), an FcγRIIA blocking antibody, anti-C5 monoclonal antibody (50 μg/ml) or isotype controls before adding <t>PF4(P)/heparin(H)</t> antigen and KKO. As shown, C3 activation was inhibited by C1/C3 blocking agents, but not by anti-C5 or anti-FcγRIIA. ***p<0.0001, ns=not significant, using the One-way ANOVA with Tukey’s multiple comparisons test (B) Inhibitory concentration curve of complement inhibitors. The inhibitory concentration leading to half-maximal C3c generation (IC 50 ) was determined in the immunocapture assay, by incubating healthy donor whole blood with increasing concentrations (x-axis) of complement inhibitors as indicated in the graph. Pre-incubation of whole blood with inhibitors was followed by addition of PF4, H and KKO to form in situ ICs and complement activation measured as described in subheading 3.1.2 . Classical pathway (CP) and CP/alternative pathway (AP) inhibitors inhibited complement activation but AP pathway specific inhibitor had no effect. Graph shows the C3c generated relative to KKO ICs <t>(PF4/H/KKO).</t> Fig. 3a adapted from Blood[ 9 ] with permission from American Society of Hematology. Fig 3b adapted from Journal of Thrombosis and Haemostasis [ 11 ] with permission from the International Society on Thrombosis and Haemostasis.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_2641/pmc13712641/pmc13712641__nihms-2217124-f0004.jpg)